Código QR (código de barras bidimensional)

Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

Background/Aims Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn’s disease (CD). Refractory disease is common, a combination of advanced drug therapies may be required to obtain maximal eff...

ver descrição completa

Na minha lista:
Principais autores: Robert Gilmore, Amrutha Murali, Amirah Etchegaray, Ei Swe, Yoon-Kyo An, Jakob Begun
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Association for the Study of Intestinal Diseases 2025-10-01
coleção:Intestinal Research
Assuntos:
upadacitinib
vedolizumab
combination therapy
ulcerative colitis
crohn disease
Acesso em linha:http://irjournal.org/upload/pdf/ir-2024-00174.pdf
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados